Pharma Mar Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Public

  • Employees
  • 509

Employees

  • Stock Symbol
  • PHM

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $43.27
  • (As of Monday Closing)

Pharma Mar General Information

Description

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
MAD
Corporate Office
  • Avenida De los Reyes, 1
  • 28770 Colmenar Viejo
  • Spain
+34 918 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharma Mar Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$43.27 $42.56 $27.82 - $48.23 $755M 17.4M 43.8K $0.12

Pharma Mar Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 411,813 663,621 1,098,508 978,458
Revenue 175,966 171,133 206,436 271,729
EBITDA (1,161) 483 53,822 122,622
Net Income 2,199 1,230 51,893 109,787
Total Assets 360,577 376,411 421,730 417,094
Total Debt 43,477 48,272 45,716 55,856
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharma Mar Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharma Mar‘s full profile, request access.

Request a free trial

Pharma Mar Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of mar
Other Pharmaceuticals and Biotechnology
Colmenar Viejo, Spain
509 As of 2023
00.00
000000000000 00.00

00000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mi
000000000000000
Mumbai, India
00000 As of 0000
0000
000000000 0000

000000

, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
000000000000000
Lagos, Nigeria
00 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharma Mar Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lupin Corporation Mumbai, India 00000 0000 000000000 0000
GlaxoSmithKline Consumer Nigeria Corporation Lagos, Nigeria 00 00000000
Cipla Corporation Mumbai, India 00000 000000&0
You’re viewing 3 of 3 competitors. Get the full list »

Pharma Mar Patents

Pharma Mar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022381992-A1 Lurbinectedin and atezolizumab combinations Pending 08-Nov-2021 00000000000
CA-3237009-A1 Lurbinectedin and atezolizumab combinations Pending 08-Nov-2021 00000000000
AU-2022369058-A1 Antitumoral compounds Pending 22-Oct-2021 0000000000
CA-3235048-A1 Antitumoral compounds Pending 22-Oct-2021 0000000000
AU-2022277799-A1 Dosage regimens for ecubectedin Pending 19-May-2021 A61K31/4995
To view Pharma Mar’s complete patent history, request access »

Pharma Mar Executive Team (8)

Name Title Board Seat
José Sousa-Faro Ph.D Founder, President, Chief Executive Officer & Chairman
Maria de Francia Caballero Chief Financial Officer
Pascal Besman Chief Operating Officer
José Jimeno Ph.D Medical Director, Virology B.U.
Heiner Pieper Vice President, Business Development & Licensing
You’re viewing 5 of 8 executive team members. Get the full list »

Pharma Mar Board Members (5)

Name Representing Role Since
000 000 0000000000 Self Board Member 000 0000
00000000 00000 Pharma Mar Board Member 000 0000
0000000000 0000000 Pharma Mar Board Member 000 0000
0000000 0000000 Pharma Mar Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Pharma Mar Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharma Mar Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharma Mar‘s full profile, request access.

Request a free trial

Pharma Mar Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zeltia 02-Nov-2014 0000000000 Biotechnology
To view Pharma Mar’s complete acquisitions history, request access »

Pharma Mar ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

25.23 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Pharma Mar’s complete esg history, request access »

Pharma Mar FAQs

  • When was Pharma Mar founded?

    Pharma Mar was founded in 1986.

  • Who is the CEO of Pharma Mar?

    José Sousa-Faro Ph.D is the CEO of Pharma Mar.

  • Where is Pharma Mar headquartered?

    Pharma Mar is headquartered in Colmenar Viejo, Spain.

  • What is the size of Pharma Mar?

    Pharma Mar has 509 total employees.

  • What industry is Pharma Mar in?

    Pharma Mar’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Pharma Mar a private or public company?

    Pharma Mar is a Public company.

  • What is Pharma Mar’s stock symbol?

    The ticker symbol for Pharma Mar is PHM.

  • What is the current stock price of Pharma Mar?

    As of 22-Jul-2024 the stock price of Pharma Mar is $43.27.

  • What is the current market cap of Pharma Mar?

    The current market capitalization of Pharma Mar is $755M.

  • What is Pharma Mar’s current revenue?

    The trailing twelve month revenue for Pharma Mar is $176M.

  • Who are Pharma Mar’s competitors?

    Lupin, GlaxoSmithKline Consumer Nigeria, and Cipla are competitors of Pharma Mar.

  • What is Pharma Mar’s annual earnings per share (EPS)?

    Pharma Mar’s EPS for 12 months was $0.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »